Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!
Quiz|Articles|September 27, 2026 (Updated: September 23, 2026)
NeurologyLive® Brain Games: September, 2026
Author(s)Louie Pasculli, Marco Meglio
Listen
0:00 / 0:00
Key Takeaways
- Weekly publication cadence is Sunday morning, with content written by physicians, clinicians, and neurological care and advocacy experts.
- Questions span major neurology domains, including dementia/Alzheimer disease, epilepsy, headache, movement disorders, multiple sclerosis, neuromuscular and sleep disorders, and stroke.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is clinical trial results in Alzheimer disease!
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of clinical trial results in Alzheimer disease!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
A 76-year-old patient with early symptomatic Alzheimer disease is being evaluated for antiamyloid therapy. The clinician explains that the treatment is intended to slow disease progression rather than reverse established cognitive impairment. Which finding from the phase 3 CLARITY AD trial most directly supports this therapeutic rationale for lecanemab?
In the phase 3 TRAILBLAZER-ALZ 2 trial, donanemab was evaluated in participants with early symptomatic Alzheimer disease. Which trial characteristic is most important when interpreting the reported clinical efficacy?
A clinical trial of an antiamyloid monoclonal antibody demonstrates a statistically significant reduction in decline on a cognitive-functional composite but also reports an increased incidence of ARIA-E compared with placebo. Which interpretation is most appropriate?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related to this article
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
2
FDA Grants Fast Track Designation to Apitegromab for Facioscapulohumeral Muscular Dystrophy
3
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
4
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
5